Integer Holdings posts strong Q3 results with earnings and revenue beat, but shares plunge on a softer 2026 growth outlook.
The headline numbers for Integer (ITGR) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors with an interest in Medical - Instruments stocks have likely encountered both Integer (ITGR) and SONOVA HOLDING (SONVY). But which of these two companies is the best option for those looking for undervalued stocks?
Investors interested in Medical - Instruments stocks are likely familiar with Integer (ITGR) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Integer Holdings Corporation (NYSE:ITGR ) Q2 2025 Earnings Conference Call July 24, 2025 9:00 AM ET Company Participants Diron Smith - Executive VP & CFO Joseph W. Dziedzic - President, CEO & Director Payman Khales - Chief Operating Officer Sanjiv Arora - Senior Vice President of Strategy, Business Development and Investor Relations Conference Call Participants Andrew Harris Cooper - Raymond James & Associates, Inc., Research Division Brett Adam Fishbin - KeyBanc Capital Markets Inc., Research Division Craig William Bijou - BofA Securities, Research Division Joanne Karen Wuensch - Citigroup Inc., Research Division Matthew Oliver O'Brien - Piper Sandler & Co., Research Division Nathan Treybeck - Wells Fargo Securities, LLC, Research Division Richard Samuel Newitter - Truist Securities, Inc., Research Division Suraj Kalia - Oppenheimer & Co. Inc., Research Division Operator Thank you for standing by.
ITGR posts strong second-quarter revenue growth, but EPS misses estimate despite solid segment momentum.
Integer (ITGR) came out with quarterly earnings of $1.55 per share, missing the Zacks Consensus Estimate of $1.57 per share. This compares to earnings of $1.3 per share a year ago.
Investors with an interest in Medical - Instruments stocks have likely encountered both Integer (ITGR) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.